Influenza,CAUSE_OF_DEATH
Vaccination,O
and,O
COVID19,O
Mortality,O
in,O
the,O
Claudio,PERSON
Zanet,PERSON
‐,O
tini1,O
.,O
*,O
.,O
Mohamed,PERSON
Omar2,PERSON
.,O
*,O
.,O
Wikum,O
Dinalankara1,O
.,O
Eddie,PERSON
Luidy,PERSON
Ima,PERSON
‐,PERSON
da1,O
.,O
Elizabeth,PERSON
Colantuoni3,PERSON
.,O
Giovanni,PERSON
Parmigiani4,O
.5,O
.,O
and,O
Luigi,PERSON
Marchionni1,O
.,O
+,O
of,O
Pathology,O
and,O
Laboratory,O
Medicine,O
.,O
Weill,PERSON
Cornell,PERSON
Medicine,O
.,O
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
.,O
NY,STATE_OR_PROVINCE
.,O
USA,COUNTRY
COVID,O
‐,O
19,NUMBER
mortality,O
rate,O
is,O
higher,O
in,O
the,O
elderly,O
and,O
in,O
those,O
with,O
preexisting,O
chronic,O
medical,O
condi,O
‐,O
tions,O
.,O
The,O
elderly,O
also,O
suffer,O
from,O
increased,O
morbidity,O
and,O
mor,O
‐,O
tality,O
from,O
seasonal,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
.,O
and,O
thus,O
annual,SET
in,O
‐,O
fluenza,O
vaccination,O
is,O
recommended,O
for,O
them,O
.,O
In,O
this,O
study,O
.,O
we,O
explore,O
a,O
possible,O
area,O
‐,O
level,O
association,O
between,O
influenza,CAUSE_OF_DEATH
vac,O
‐,O
cination,O
coverage,O
in,O
people,O
aged,O
65,DURATION
years,DURATION
and,O
older,O
and,O
the,O
num,O
‐,O
ber,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
To,O
this,O
end,O
.,O
we,O
used,O
COVID,O
‐,O
19,NUMBER
data,O
until,O
June,DATE
10,DATE
.,DATE
2020,DATE
together,O
with,O
population,O
health,O
data,O
for,O
the,O
United,COUNTRY
States,COUNTRY
at,O
the,O
county,O
level,O
.,O
We,O
fit,O
quasi,O
‐,O
Poisson,O
regres,O
‐,O
sion,O
models,O
using,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
in,O
the,O
elderly,O
population,O
as,O
the,O
independent,RELIGION
variable,O
and,O
the,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
outcome,O
variable,O
.,O
We,O
adjusted,O
for,O
a,O
wide,O
ar,O
‐,O
ray,O
of,O
potential,O
confounding,O
variables,O
using,O
both,O
county,O
‐,O
level,O
generalized,O
propensity,O
scores,O
for,O
influenza,CAUSE_OF_DEATH
vaccination,O
rates,O
.,O
as,O
well,O
as,O
direct,O
adjustment,O
.,O
Our,O
results,O
suggest,O
that,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
in,O
the,O
elderly,O
population,O
is,O
negatively,O
as,O
‐,O
sociated,O
with,O
mortality,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
This,O
finding,O
is,O
robust,O
to,O
using,O
different,O
analysis,O
periods,O
.,O
different,O
thresholds,O
for,O
inclu,O
‐,O
sion,O
of,O
counties,O
.,O
and,O
a,O
variety,O
of,O
methodologies,O
for,O
confounding,O
adjustment,O
.,O
In,O
conclusion,O
.,O
our,O
results,O
suggest,O
a,O
potential,O
pro,O
‐,O
tective,O
effect,O
of,O
the,O
influenza,CAUSE_OF_DEATH
vaccine,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
in,O
the,O
elderly,O
population,O
.,O
The,O
significant,O
public,O
health,O
implica,O
‐,O
tions,O
of,O
this,O
possibility,O
point,O
to,O
an,O
urgent,O
need,O
for,O
studying,O
the,O
relationship,O
between,O
influenza,CAUSE_OF_DEATH
vaccination,O
and,O
COVID,O
‐,O
19,NUMBER
mor,O
‐,O
tality,O
at,O
the,O
individual,O
level,O
.,O
to,O
investigate,O
both,O
the,O
epidemi,O
‐,O
ology,O
and,O
any,O
underlying,O
biological,O
mechanism,O
.,O
COVID,O
‐,O
19,NUMBER
.,O
a,O
dis,O
‐,O
ease,O
caused,O
by,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
has,O
become,O
a,O
global,O
health,O
threat,O
owing,O
to,O
its,O
high,O
rate,O
of,O
spread,O
and,O
mortality,O
.,O
By,O
June,DATE
10,DATE
.,DATE
2020,DATE
.,O
the,O
total,O
number,O
of,O
cases,O
worldwide,O
had,O
reached,O
more,O
than,O
7,NUMBER
million,NUMBER
with,O
approximately,O
411.195,NUMBER
confirmed,O
deaths1,O
.,O
The,O
disease,CAUSE_OF_DEATH
started,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
in,O
December,DATE
2019,DATE
as,O
a,O
zoonotic,O
infection,CAUSE_OF_DEATH
.,O
but,O
strong,O
evidence,O
suggests,O
that,O
efficient,O
human,O
‐,O
to,O
‐,O
human,O
transmission,O
started,O
as,O
early,O
as,O
mid,O
‐,O
December,DATE
20192,NUMBER
.,O
Such,O
person,O
‐,O
to,O
‐,O
person,O
transmission,O
occurs,O
mainly,O
through,O
respiratory,O
droplets,O
with,O
sev,O
‐,O
eral,O
studies,O
reporting,O
the,O
possibility,O
of,O
spread,O
from,O
asympto,O
‐,O
matic,O
patients3,O
.,O
4,NUMBER
.,O
Most,O
symptomatic,O
infections,CAUSE_OF_DEATH
are,O
mild,O
with,O
nearly,O
14,PERCENT
%,PERCENT
of,O
infected,O
individuals,O
developing,O
severe,O
disease,CAUSE_OF_DEATH
with,O
dyspnea,O
and,O
hypoxia,O
.,O
Critical,O
illness,CAUSE_OF_DEATH
has,O
been,O
seen,O
in,O
only,O
5,PERCENT
%,PERCENT
of,O
cases,O
in,O
the,O
form,O
of,O
septic,O
shock,O
and,O
respiratory,O
and,O
multi,O
‐,O
organ,O
failure5,O
.,O
In,O
symptomatic,O
patients,O
.,O
the,O
most,O
frequent,O
presenta,O
‐,O
tion,O
is,O
pneumonia,CAUSE_OF_DEATH
.,O
manifested,O
by,O
fever,CAUSE_OF_DEATH
.,O
fatigue,O
.,O
dry,O
cough,O
.,O
dysp,O
‐,O
nea,O
.,O
and,O
pulmonary,O
infiltration6,O
.,O
7,NUMBER
.,O
Other,O
symptoms,O
have,O
also,O
been,O
reported,O
including,O
.,O
but,O
not,O
limited,O
to,O
sore,O
throat,O
.,O
nausea,O
.,O
diarrhea,O
.,O
myalgia,O
.,O
confusion,O
.,O
anosmia,O
.,O
and,O
other,O
taste,O
abnormali,O
‐,O
ties8,O
.,O
9,NUMBER
.,O
The,O
risk,O
of,O
developing,O
severe,O
complications,CAUSE_OF_DEATH
and,O
mor,O
‐,O
tality,O
rates,O
is,O
higher,O
in,O
the,O
elderly,O
.,O
in,O
males,O
.,O
and,O
in,O
patients,O
with,O
co,O
‐,O
morbidities,O
.,O
especially,O
hypertension,CAUSE_OF_DEATH
.,O
diabetes,CAUSE_OF_DEATH
.,O
and,O
chronic,O
respiratory,O
conditions,O
including,O
asthma,CAUSE_OF_DEATH
and,O
chronic,O
ob,O
‐,O
structive,O
pulmonary,O
disease,CAUSE_OF_DEATH
(,O
COPD,O
),O
10,NUMBER
.,O
11,NUMBER
.,O
Acute,O
respiratory,O
dis,O
‐,O
tress,O
syndrome,O
(,O
ARDS,ORGANIZATION
),O
is,O
the,O
most,O
common,O
complication,O
in,O
people,O
with,O
severe,O
illness,CAUSE_OF_DEATH
with,O
the,O
incidence,O
being,O
higher,O
in,O
the,O
older,O
population,O
.,O
Seasonal,O
respiratory,O
viral,O
co,O
‐,O
infections,CAUSE_OF_DEATH
.,O
most,O
com,O
‐,O
monly,O
influenza,CAUSE_OF_DEATH
A,O
and,O
B,O
.,O
have,O
been,O
reported,O
in,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients12,O
.,O
13,NUMBER
.,O
Seasonal,O
influenza,CAUSE_OF_DEATH
causes,O
distinct,O
outbreaks,O
ev,O
‐,O
ery,O
year,DURATION
with,O
the,O
attack,CAUSE_OF_DEATH
rate,O
varying,O
from,O
10,PERCENT
%,PERCENT
to,O
20,PERCENT
%,PERCENT
.,O
Similar,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
the,O
morbidity,O
and,O
mortality,O
are,O
also,O
higher,O
in,O
the,O
old,O
‐,O
er,O
population,O
and,O
in,O
patients,O
with,O
chronic,O
comorbidities14,O
.,O
Thus,O
.,O
routine,O
annual,SET
vaccination,O
is,O
recommended,O
in,O
these,O
groups,O
.,O
While,O
in,O
the,O
elderly,O
the,O
vaccine,O
is,O
of,O
clear,O
benefit,O
.,O
the,O
benefit,O
is,O
even,O
higher,O
in,O
those,O
with,O
high,O
‐,O
risk,O
illnesses,O
.,O
The,O
absolute,O
risk,O
reduction,O
from,O
the,O
vaccine,O
was,O
2,NUMBER
to,O
4,NUMBER
folds,O
higher,O
in,O
the,O
elderly,O
population,O
with,O
chronic,O
underlying,O
conditions,O
compared,O
to,O
the,O
healthy,O
population,O
of,O
the,O
same,O
age,O
group,O
.,O
even,O
when,O
there,O
was,O
a,O
poor,O
match,O
between,O
the,O
vaccine,O
and,O
circulating,O
strains15,O
.,O
and,O
when,O
the,O
vaccine,O
effectiveness,O
rate,O
was,O
as,O
low,O
as,O
10,PERCENT
%,PERCENT
16,NUMBER
.,O
Another,O
study,O
found,O
that,O
the,O
vaccine,O
was,O
effective,O
at,O
reducing,O
the,O
rate,O
of,O
hospitalization,O
from,O
pneumonia,CAUSE_OF_DEATH
and,O
also,O
the,O
rate,O
of,O
death,O
in,O
elderly,O
people,O
with,O
chronic,O
lung,O
diseases17,O
.,O
Interestingly,O
.,O
Tak,O
‐,O
sler,O
et,O
al.,O
18,NUMBER
found,O
an,O
inverse,O
relationship,O
between,O
influenza,CAUSE_OF_DEATH
vaccine,O
coverage,O
in,O
adults,O
aged,O
between,O
18,NUMBER
and,O
64,DURATION
years,DURATION
and,O
in,O
‐,O
fluenza,O
‐,O
related,O
illness,CAUSE_OF_DEATH
in,O
the,O
older,O
population,O
(,O
>,O
=,O
65,DURATION
years,DURATION
),O
which,O
can,O
be,O
explained,O
by,O
reduced,O
transmission,O
in,O
the,O
community,O
.,O
Since,O
there,O
is,O
no,O
effective,O
treatment,O
or,O
vaccine,O
available,O
for,O
COVID,O
‐,O
19,NUMBER
to,O
this,O
date,O
.,O
other,O
measures,O
have,O
to,O
be,O
taken,O
to,O
reduce,O
the,O
morbidity,O
and,O
mortality,O
of,O
this,O
disease,CAUSE_OF_DEATH
.,O
Public,O
health,O
mea,O
‐,O
sures,O
like,O
isolation,O
.,O
quarantine,O
.,O
and,O
social,O
distancing,O
are,O
being,O
used,O
worldwide,O
to,O
contain,O
outbreaks,O
and,O
reduce,O
the,O
spread,O
of,O
the,O
disease19,O
.,O
These,O
measures,O
are,O
key,O
not,O
only,O
to,O
mitigate,O
the,O
virus,O
transmission,O
but,O
also,O
to,O
better,O
manage,O
healthcare,O
resources20,O
.,O
A,O
plausible,O
conjecture,O
is,O
that,O
reducing,O
the,O
rate,O
of,O
chronic,O
and,O
acute,O
respiratory,O
comorbidities,O
in,O
high,O
‐,O
risk,O
populations,O
.,O
could,O
in,O
turn,O
lead,O
to,O
a,O
reduction,O
in,O
the,O
complications,CAUSE_OF_DEATH
and,O
deaths,O
asso,O
‐,O
ciated,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Based,O
on,O
this,O
.,O
it,O
could,O
be,O
hypothesized,O
that,O
routine,O
influenza,CAUSE_OF_DEATH
vaccination,O
may,O
be,O
associated,O
with,O
lower,O
morbidity,O
and,O
mortality,O
from,O
COVID,O
‐,O
19,NUMBER
because,O
immunized,O
individu,O
‐,O
als,O
will,O
have,O
a,O
lower,O
rate,O
of,O
respiratory,O
complications,CAUSE_OF_DEATH
from,O
in,O
‐,O
fluenza,O
.,O
and,O
thus,O
will,O
have,O
a,O
better,O
baseline,O
health,O
have,O
been,O
recently,DATE
reported,O
among,O
army,O
personnel,O
who,O
received,O
influenza,CAUSE_OF_DEATH
vaccination21,O
.,O
Therefore,O
.,O
it,O
is,O
possible,O
that,O
influenza,CAUSE_OF_DEATH
vaccina,O
‐,O
tion,O
may,O
increase,O
the,O
susceptibility,O
to,O
SARS,O
‐,O
CoV2,O
infection,CAUSE_OF_DEATH
.,O
and,O
thus,O
be,O
associated,O
with,O
increased,O
COVID,O
‐,O
19,NUMBER
morbidity,O
.,O
and,O
mortal,O
‐,O
ity,O
.,O
through,O
immune,O
‐,O
mediated,O
mechanisms,O
like,O
antibody,O
‐,O
dependent,O
enhancement,O
(,O
ADE,O
),O
22,NUMBER
.,O
Motivated,O
by,O
these,O
observations,O
.,O
we,O
inves,O
‐,O
tigate,O
whether,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
is,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
mortality,O
.,O
and,O
.,O
if,O
so,O
.,O
in,O
which,O
direction,O
.,O
To,O
this,O
end,O
.,O
we,O
analyze,O
COVID,O
‐,O
19,NUMBER
mortality,O
rate,O
and,O
influenza,CAUSE_OF_DEATH
vaccination,O
cov,O
‐,O
erage,O
in,O
the,O
United,COUNTRY
States,COUNTRY
(,O
US,COUNTRY
),O
at,O
the,O
county,O
level,O
.,O
While,O
an,O
area,O
‐,O
level,O
association,O
can,O
only,O
provide,O
preliminary,O
evidence,O
.,O
this,O
issue,O
requires,O
urgent,O
attention,O
.,O
and,O
the,O
data,O
we,O
collected,O
is,O
the,O
most,O
effective,O
in,O
shedding,O
light,O
on,O
it,O
at,O
this,O
time,O
.,O
In,O
our,O
analysis,O
.,O
we,O
take,O
great,O
care,O
to,O
adjust,O
for,O
important,O
social,O
.,O
economic,O
.,O
and,O
health,O
determinants,O
.,O
to,O
mitigate,O
the,O
intrinsic,O
lim,O
‐,O
itation,O
of,O
observational,O
studies,O
based,O
on,O
aggregated,O
data,O
.,O
Mate,O
‐,O
rials,O
and,O
Methods,O
Social,O
.,O
economic,O
.,O
demographic,O
.,O
and,O
COVID,O
‐,O
19,NUMBER
variables,O
To,O
evaluate,O
the,O
impact,O
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
.,O
we,O
collected,O
and,O
analyzed,O
data,O
on,O
vaccination,O
coverage,O
.,O
COVID,O
‐,O
19,NUMBER
mortality,O
.,O
and,O
other,O
important,O
social,O
.,O
econom,O
‐,O
ic,O
.,O
and,O
health,O
variables,O
from,O
the,O
United,COUNTRY
States,COUNTRY
of,COUNTRY
America,COUNTRY
(,O
US,COUNTRY
),O
.,O
The,O
cumulative,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
cases,O
and,O
deaths,O
were,O
consid,O
‐,O
ered,O
until,O
June,DATE
10,DATE
.,DATE
2020,DATE
.,O
which,O
aggregates,O
and,O
combines,O
data,O
re,O
‐,O
ported,O
by,O
national,O
and,O
state,O
sources,O
.,O
Up,O
to,O
date,O
statistics,O
on,O
COVID,O
‐,O
19,NUMBER
testing,O
for,O
that,O
aggregates,O
metrics,O
from,O
different,O
sources,O
regarding,O
the,O
COVID,O
‐,O
19,NUMBER
epidemic,O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
All,O
these,O
statistics,O
include,O
cases,O
in,O
which,O
the,O
presence,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
was,O
laboratory,O
‐,O
confirmed,O
.,O
and,O
others,O
in,O
which,O
it,O
was,O
pre,O
‐,O
sumed,O
and,O
considered,O
the,O
probable,O
cause,O
of,O
death23,O
.,O
For,O
Rhode,PERSON
Island,O
.,O
the,O
JHU,O
repository,O
reported,O
deaths,O
only,O
at,O
the,O
state,O
lev,O
‐,O
el,O
.,O
older,O
.,O
medical,O
conditions,O
.,O
and,O
tobacco,CAUSE_OF_DEATH
use,O
(,O
year,DATE
2017,DATE
),O
were,O
obtained,O
from,O
the,O
Center,ORGANIZATION
of,ORGANIZATION
Medicare,ORGANIZATION
Disparity,ORGANIZATION
Office,ORGANIZATION
of,O
composi,O
‐,O
tion,O
.,O
gender,O
.,O
race,O
.,O
age,O
.,O
and,O
poverty,O
levels,O
(,O
year,DATE
2018,DATE
),O
in,O
each,O
US,COUNTRY
county,O
were,O
retrieved,O
from,O
the,O
Census,ORGANIZATION
Bureau,ORGANIZATION
Data,ORGANIZATION
and,O
software,O
availability,O
.,O
All,O
data,O
used,O
in,O
this,O
study,O
.,O
along,O
with,O
detailed,O
information,O
about,O
data,O
sources,O
.,O
are,O
available,O
com,O
/,O
c1au6i0,O
/,O
covid19_influenza,O
.,O
All,O
data,O
pre,O
‐,O
processing,O
and,O
sta,O
‐,O
tistical,O
analyses,O
in,O
this,O
study,O
were,O
performed,O
using,O
the,O
R,O
pro,O
‐,O
gramming,O
language25,O
.,O
and,O
libraries,O
from,O
the,O
tidyverse,O
suite26,O
.,O
27,NUMBER
.,O
Inclusion,O
criteria,O
.,O
Information,O
was,O
available,O
for,O
a,O
total,O
of,O
3243,DATE
counties,O
across,O
the,O
50,NUMBER
states,O
and,O
the,O
Washington,STATE_OR_PROVINCE
D.C.,LOCATION
district,O
.,O
between,O
January,DATE
22,DATE
.,DATE
2020,DATE
and,O
June,DATE
10,DATE
.,DATE
2020,DATE
.,O
For,O
a,O
total,O
of,O
1219,DATE
COVID,O
‐,O
19,NUMBER
deaths,O
.,O
the,O
county,O
of,O
the,O
deceased,O
was,O
unknown,O
.,O
Those,O
deaths,O
were,O
omitted,O
from,O
the,O
analysis,O
since,O
also,O
informa,O
‐,O
tion,O
regarding,O
the,O
variable,O
of,O
interest,O
and,O
the,O
confounders,O
were,O
not,O
available,O
.,O
As,O
of,O
the,DATE
last,DATE
day,DATE
of,O
observation,O
.,O
a,O
total,O
of,O
206,NUMBER
counties,O
did,O
not,O
report,O
any,O
confirmed,O
cases,O
.,O
To,O
limit,O
the,O
impact,O
of,O
limited,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
community,O
circulation,O
and,O
exposure,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
.,O
only,O
counties,O
with,O
at,O
least,O
10,NUMBER
include,O
the,O
duration,O
of,O
the,O
outbreak,O
(,O
in,O
the,O
form,O
of,O
the,O
number,O
of,O
days,DURATION
elapsed,O
since,O
the,O
first,ORDINAL
reported,O
COVID,O
‐,O
19,NUMBER
case,O
),O
among,O
the,O
con,O
‐,O
founding,O
variables,O
.,O
For,O
all,O
other,O
variables,O
.,O
we,O
used,O
the,O
latest,O
available,O
year,DURATION
information,O
.,O
as,O
summarized,O
below,O
.,O
Potential,O
Con,O
‐,O
founders,O
Overall,O
.,O
the,O
initial,O
set,O
of,O
variables,O
related,O
to,O
popula,O
‐,O
tion,O
demographics,O
.,O
clinical,O
and,O
territory,O
character,O
‐,O
istics,O
was,O
large,O
(,O
300,NUMBER
),O
.,O
In,O
our,O
analyses,O
.,O
therefore,O
.,O
we,O
selected,O
representa,O
‐,O
tive,O
variables,O
from,O
each,O
important,O
category,O
.,O
and,O
avoided,O
highly,O
correlated,O
pairs,O
.,O
Specifically,O
.,O
the,O
following,O
variables,O
were,O
in,O
‐,O
cluded,O
in,O
our,O
models,O
:,O
1,NUMBER
.,O
Household,O
‐,O
related,O
variables,O
:,O
a,O
),PERCENT
%,PERCENT
of,O
family,O
households,O
.,O
b,O
),PERCENT
%,PERCENT
of,O
families,O
with,O
a,O
single,O
parent,O
.,O
and,O
c,O
),O
%,O
of,O
households,O
with,O
access,O
to,O
internet,O
.,O
Note,O
that,O
a,O
family,O
is,O
defined,O
by,O
the,O
US,COUNTRY
Census,O
as,O
consisting,O
of,O
a,O
householder,O
and,O
one,NUMBER
or,O
more,O
other,O
people,O
living,O
in,O
the,O
same,O
household,O
who,O
are,O
related,O
to,O
the,O
householder,O
by,O
birth,O
.,O
marriage,O
.,O
or,O
adoption,O
.,O
2,NUMBER
.,O
Socioeco,O
‐,O
nomic,O
‐,O
and,O
healthcare,O
‐,O
related,O
variables,O
:,O
a,O
),O
median,O
income,O
.,O
b,O
),O
hospital,O
beds,O
per,O
person,O
.,O
c,O
),O
number,O
of,O
COVID,O
‐,O
19,NUMBER
tests,O
(,O
at,O
the,O
state,O
level,O
),O
.,O
d,O
),O
number,O
of,O
days,DURATION
since,O
the,O
first,ORDINAL
case,O
in,O
that,O
county,O
.,O
3,NUMBER
.,O
Education,O
‐,O
related,O
variables,O
:,O
(,O
a,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
a,O
bachelor,TITLE
degree,O
.,O
4,NUMBER
.,O
Race,O
‐,O
related,O
variables,O
(,PERCENT
%,PERCENT
of,O
people,O
in,O
the,O
population,O
of,O
the,O
following,O
races,O
),O
:,O
a,O
),O
Asian,NATIONALITY
.,O
b,O
),O
Black,O
or,O
African,NATIONALITY
‐,O
American,NATIONALITY
.,O
c,O
),O
Latino,O
or,O
Hispanic,O
.,O
d,O
),O
Native,MISC
American,NATIONALITY
.,O
e,O
),O
Caucasian,MISC
or,O
White,O
.,O
f,O
),O
other,O
races,O
.,O
g,O
),O
belonging,O
to,O
two,NUMBER
or,O
more,O
races,O
.,O
5,NUMBER
.,O
Demographic,MISC
variables,O
:,O
a,O
),PERCENT
%,PERCENT
of,O
people,O
65,NUMBER
‐,O
year,DURATION
of,O
age,O
or,O
older,O
.,O
b,O
),O
median,O
age,O
.,O
c,O
),O
sex,O
ratio,O
(,O
males,O
per,O
100,NUMBER
females,O
),O
.,O
and,O
d,O
),O
child,O
dependency,O
ratio,O
(,O
ratio,O
between,O
population,O
under,O
18,NUMBER
years,DURATION
and,O
population,O
18,NUMBER
‐,O
to,O
‐,O
64,NUMBER
),O
.,O
6,NUMBER
.,O
Medical,O
conditions,O
or,O
dis,O
‐,O
eases,O
(,PERCENT
%,PERCENT
of,O
people,O
65,NUMBER
‐,O
year,DURATION
of,O
age,O
or,O
older,O
with,O
),O
:,O
a,O
),O
dementia,CAUSE_OF_DEATH
.,O
b,O
),O
asthma,CAUSE_OF_DEATH
.,O
c,O
),O
atrial,O
fibrillation,O
.,O
d,O
),O
breast,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
.,O
e,O
),O
colorectal,O
cancer,CAUSE_OF_DEATH
.,O
f,O
),O
lung,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
.,O
g,O
),O
obstructive,O
pulmonary,O
disease,CAUSE_OF_DEATH
.,O
h,O
),O
chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
i,O
),O
depression,O
.,O
j,O
),O
diabetes,CAUSE_OF_DEATH
.,O
k,NUMBER
),O
heart,O
failure,O
.,O
l,O
),O
hypertension,CAUSE_OF_DEATH
.,O
m,O
),O
ischemic,CAUSE_OF_DEATH
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
n,O
),O
obesity,O
.,O
o,O
),O
rheumatoid,O
arthritis,O
p,O
),O
stroke,CAUSE_OF_DEATH
and,O
transient,O
ischemic,O
attack,CAUSE_OF_DEATH
.,O
and,O
q,O
),O
tobacco,CAUSE_OF_DEATH
use,O
.,O
7,NUMBER
.,O
Environmental,O
variables,O
:,O
a,O
),O
fine,O
particu,O
‐,O
late,O
matter,O
(,O
g,O
/,O
m2,O
.,O
average,O
of,O
years,DATE
2000,DATE
to,O
2016,DATE
),O
.,O
b,O
),O
winter,DATE
and,O
summer,DATE
temperature,O
.,O
and,O
c,O
),O
winter,DATE
and,O
summer,DATE
humidity,O
.,O
Statisti,O
‐,O
cal,O
Modeling,O
Generalized,O
linear,O
model,TITLE
.,O
We,O
are,O
interested,O
in,O
esti,O
‐,O
mating,O
the,O
change,O
in,O
the,O
COVID,O
‐,O
19,NUMBER
mortality,O
rate,O
associated,O
with,O
a,O
change,O
in,O
the,O
county,O
‐,O
level,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
.,O
To,O
this,O
end,O
.,O
we,O
used,O
a,O
quasi,O
‐,O
Poisson,O
regression,O
with,O
the,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
response,O
variable,O
.,O
the,O
influenza,CAUSE_OF_DEATH
vac,O
‐,O
cination,O
coverage,O
in,O
people,O
65,NUMBER
‐,O
year,DURATION
of,O
age,O
and,O
older,O
as,O
an,O
inde,O
‐,O
pendent,O
variable,O
.,O
and,O
the,O
population,O
size,O
of,O
each,O
area,O
as,O
offset,O
.,O
We,O
calculated,O
the,O
mortality,O
rate,O
ratio,O
(,O
MRR,O
),O
using,O
the,O
the,O
R,O
package,O
oddratios28,O
.,O
The,O
MRR,O
represents,O
the,O
ratio,O
of,O
COVID,O
‐,O
19,NUMBER
mortality,O
corresponding,O
to,O
an,O
increase,O
of,O
10,PERCENT
%,PERCENT
in,O
the,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
.,O
We,O
chose,O
population,O
mortality,O
.,O
in,O
contrast,O
to,O
mortality,O
among,O
the,O
infected,O
population,O
.,O
to,O
remove,O
the,O
effect,O
of,O
inconsistent,O
COVID,O
‐,O
19,NUMBER
testing,O
policies,O
across,O
areas,O
.,O
We,O
con,O
‐,O
trolled,O
for,O
potential,O
confounding,O
both,O
via,O
generalized,O
propensity,O
scores,O
and,O
direct,O
adjustment,O
.,O
as,O
described,O
next,O
.,O
Confounding,O
ad,O
‐,O
justment,O
with,O
generalized,O
propensity,O
score,O
.,O
We,O
estimated,O
a,O
gener,O
‐,O
alized,O
propensity,O
score,O
(,O
PS,O
),O
model,TITLE
for,O
county,O
‐,O
level,O
rates,O
of,O
vac,O
‐,O
cination,O
over,O
65,NUMBER
‐,O
year,DURATION
of,O
age,O
by,O
regressing,O
the,O
logit,O
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
on,O
selected,O
confounding,O
variables,O
(,O
see,O
Po,O
‐,O
tential,O
Confounders,O
above,O
),O
.,O
The,O
propensity,O
score,O
is,O
a,O
balancing,O
factor,O
that,O
allows,O
to,O
correct,O
for,O
the,O
potentially,O
unequal,O
distri,O
‐,O
bution,O
of,O
explanatory,O
and,O
confounding,O
variables,O
across,O
levels,O
of,O
exposure2931,O
.,O
In,O
our,O
main,O
analyses,O
.,O
we,O
stratified,O
the,O
propensity,O
score,O
into,O
quintiles,O
.,O
and,O
then,O
used,O
these,O
as,O
a,O
factor,O
in,O
the,O
quasi,O
‐,O
Poisson,O
regression,O
analysis,O
.,O
We,O
performed,O
this,O
analysis,O
with,O
and,O
without,O
state,O
‐,O
specific,O
fixed,O
effects,O
.,O
Additionally,O
.,O
we,O
employed,O
a,O
Poisson,O
mixed,O
model,TITLE
in,O
which,O
the,O
state,O
was,O
included,O
as,O
random,O
factor,O
to,O
control,O
for,O
state,O
differences,O
.,O
We,O
also,O
used,O
the,O
PS,O
quintiles,O
to,O
perform,O
a,O
fully,O
stratified,O
analysis,O
.,O
Lastly,O
.,O
we,O
repeated,O
the,O
analysis,O
by,O
including,O
the,O
propensity,O
score,O
as,O
a,O
lin,O
‐,O
ear,O
term,O
(,O
see,O
secondary,O
analyses,O
),O
.,O
Direct,O
confounding,O
adjust,O
‐,O
ment,O
.,O
As,O
an,O
alternative,O
.,O
we,O
also,O
modeled,O
the,O
effect,O
of,O
immuniza,O
‐,O
tion,O
coverage,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
by,O
directly,O
adjusting,O
for,O
confounding,O
variables,O
via,O
linear,O
terms,O
in,O
the,O
quasi,O
‐,O
Poisson,O
re,O
‐,O
gression,O
.,O
To,O
select,O
a,O
parsimonious,O
number,O
of,O
potential,O
con,O
‐,O
founders,O
.,O
we,O
clustered,O
candidate,TITLE
variables,O
based,O
on,O
their,O
corre,O
‐,O
lation,O
with,O
each,O
other,O
households,O
.,O
b,O
),O
rate,O
of,O
hospital,O
beds,O
.,O
c,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
asthma,CAUSE_OF_DEATH
.,O
d,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
breast,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
.,O
e,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
lung,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
.,O
f,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
COPD,O
.,O
g,O
),PERCENT
%,PERCENT
of,O
people,O
with,O
hypertension,CAUSE_OF_DEATH
.,O
h,O
),O
median,O
income,O
.,O
i,O
),O
summer,DATE
temperature,O
.,O
j,O
),O
summer,DATE
humidity,O
.,O
k,NUMBER
),O
winter,DATE
temperature,O
.,O
l,O
),O
winter,DATE
humidity,O
.,O
m,O
),PERCENT
%,PERCENT
of,O
people,O
>,O
=,O
65,DURATION
years,DURATION
old,DURATION
.,O
n,O
),O
sex,O
ratio,O
.,O
and,O
o,O
),O
days,DURATION
passed,O
since,O
the,O
first,ORDINAL
case,O
.,O
Secondary,O
analyses,O
:,O
Dependency,O
on,O
counties,O
with,O
highest,O
and,O
lowest,O
infection,CAUSE_OF_DEATH
rates,O
.,O
Counties,O
with,O
extremely,O
low,O
or,O
high,O
numbers,O
of,O
confirmed,O
cases,O
(,O
and,O
deaths,O
),O
might,O
have,O
undue,O
leverage,O
on,O
statistical,O
estimates,O
.,O
To,O
explore,O
sensitivity,O
of,O
our,O
results,O
.,O
we,O
repeated,O
the,O
analysis,O
by,O
requiring,O
a,O
larger,O
minimum,O
number,O
of,O
confirmed,O
cases,O
for,O
inclusion,O
in,O
the,O
model,TITLE
(,O
ranging,O
from,O
10,NUMBER
to,NUMBER
100,NUMBER
in,O
increments,O
of,O
10,NUMBER
),O
.,O
Also,O
.,O
since,O
New,PERSON
York,PERSON
State,PERSON
has,O
the,O
highest,O
number,O
of,O
confirmed,O
cases,O
(,O
and,O
deaths,O
),O
from,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
US,COUNTRY
.,O
we,O
repeated,O
the,O
analysis,O
after,O
removing,O
all,O
53,NUMBER
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
State,LOCATION
counties,O
.,O
Finally,O
.,O
since,O
we,O
noticed,O
that,O
for,O
46,NUMBER
counties,O
.,O
no,O
deaths,O
were,O
reported,O
despite,O
the,O
large,O
number,O
of,O
cases,O
(,O
i.e.,O
.,O
exceeding,O
100,NUMBER
),O
.,O
we,O
hypothesized,O
that,O
different,O
cri,O
‐,O
teria,O
could,O
have,O
been,O
used,O
to,O
record,O
COVID,O
‐,O
19,NUMBER
related,O
deaths,O
in,O
these,O
counties,O
.,O
We,O
therefore,O
repeated,O
our,O
analysis,O
including,O
only,O
the,O
counties,O
with,O
at,O
least,O
one,NUMBER
death,O
.,O
Secondary,O
analyses,O
:,O
Sta,O
‐,O
bility,O
over,O
time,O
.,O
Our,O
analyses,O
are,O
somewhat,O
arbitrarily,O
based,O
on,O
the,O
time,O
window,O
ending,O
on,O
June,DATE
10,DATE
.,O
As,O
information,O
on,O
COVID,O
‐,O
19,NUMBER
continues,O
to,O
accrue,O
results,O
may,O
evolve,O
.,O
To,O
assess,O
stability,O
across,O
time,O
of,O
our,O
estimated,O
effects,O
.,O
we,O
repeated,O
the,O
analyses,O
with,O
the,O
data,O
available,O
at,O
different,O
points,O
over,O
approximately,O
two,DURATION
months,DURATION
.,O
Independent,RELIGION
Verification,O
:,O
Exposure,O
to,O
air,O
pollution,O
.,O
Levels,O
of,O
airborne,O
fine,O
particulate,O
matter,O
(,O
PM2,O
.5,NUMBER
),O
have,O
been,O
re,O
‐,O
ported,O
to,O
contribute,O
to,O
COVID,O
‐,O
19,NUMBER
mortality24,O
.,O
based,O
on,O
analyses,O
sharing,O
much,O
of,O
the,O
same,O
data,O
structure,O
and,O
methodology,O
with,O
what,O
done,O
here,O
.,O
To,O
provide,O
an,O
independent,RELIGION
verification,O
of,O
our,O
data,O
collection,O
and,O
analysis,O
pipeline,O
.,O
we,O
repeated,O
our,O
analysis,O
using,O
chronic,O
exposure,O
to,O
fine,O
particulate,O
matter,O
(,O
PM2,O
.5,NUMBER
),O
as,O
an,O
alter,O
‐,O
native,O
exposure,O
.,O
and,O
including,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
among,O
the,O
possible,O
confounding,O
variables,O
.,O
We,O
were,O
able,O
to,O
repro,O
‐,O
duce,O
the,O
reported,O
effect,O
of,O
PM2,O
.5,NUMBER
exposure,O
on,O
COVID,O
‐,O
19,NUMBER
death,O
rate,O
.,O
Social,O
.,O
economic,O
.,O
demographic,O
population,O
characteristics,O
and,O
COVID,O
‐,O
19,NUMBER
outcomes,O
in,O
the,O
US,COUNTRY
A,O
total,O
of,O
2034,DATE
counties,O
were,O
in,O
‐,O
cluded,O
in,O
the,O
analysis,O
.,O
The,O
median,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
in,O
people,O
65,NUMBER
‐,O
year,DURATION
of,O
age,O
is,O
45,PERCENT
%,PERCENT
.,O
The,O
COVID,O
‐,O
19,NUMBER
mortality,O
rate,O
did,O
not,O
differ,O
substantially,O
between,O
counties,O
where,O
vaccination,O
cov,O
‐,O
erage,O
was,O
above,O
the,O
median,O
(,O
20.5,NUMBER
52,NUMBER
sd,O
),O
.,O
compared,O
to,O
those,O
where,O
it,O
was,O
below,O
(,O
17.3,NUMBER
31.7,NUMBER
sd,O
),O
.,O
Counties,O
with,O
lower,O
influenza,CAUSE_OF_DEATH
‐,O
vac,O
‐,O
cination,O
coverage,O
tend,O
to,O
have,O
a,O
lower,O
level,O
of,O
education,O
and,O
in,O
‐,O
come,O
.,O
and,O
to,O
have,O
a,O
higher,O
percentage,O
of,O
Black,O
and,O
Latino,O
popula,O
‐,O
tions,O
.,O
In,O
contrast,O
.,O
counties,O
with,O
higher,O
vaccination,O
coverage,O
tend,O
to,O
be,O
more,O
affluent,O
.,O
and,O
to,O
have,O
an,O
higher,O
percentage,O
of,O
white,O
between,O
counties,O
with,O
different,O
vaccination,O
coverage,O
.,O
Vac,O
‐,O
cination,O
coverage,O
Number,O
of,O
counties,O
Death,O
rate,O
(,O
per,O
100.000,NUMBER
peo,O
‐,O
ple,O
),O
Confirmed,O
case,O
rate,O
(,O
per,O
100.000,NUMBER
people,O
),O
Number,O
of,O
days,DURATION
since,O
the,O
first,ORDINAL
case,PERCENT
%,PERCENT
family,O
households,O
%,O
families,O
with,O
only,O
one,NUMBER
parent,O
%,O
with,O
bachelor,TITLE
degree,PERCENT
%,PERCENT
with,O
Internet,PERCENT
%,PERCENT
median,O
income,O
(,O
$,MONEY
1.000,MONEY
),O
Rate,O
of,O
hospital,O
beds,O
(,O
per,O
1000,NUMBER
people,O
),PERCENT
%,PERCENT
with,O
Alzheimers,O
disease,CAUSE_OF_DEATH
%,O
with,O
asthma,PERCENT
%,PERCENT
with,O
atrial,O
fibrillation,PERCENT
%,PERCENT
with,O
breast,O
cancer,PERCENT
%,PERCENT
with,O
colorectal,O
cancer,PERCENT
%,PERCENT
with,O
lung,O
cancer,PERCENT
%,PERCENT
with,O
obstructive,O
pulmonary,O
disease,PERCENT
%,PERCENT
with,O
chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
%,O
with,O
depression,PERCENT
%,PERCENT
with,O
diabetes,CAUSE_OF_DEATH
%,O
with,O
heart,O
failure,PERCENT
%,PERCENT
with,O
hy,O
‐,O
pertension,PERCENT
%,PERCENT
with,O
ischemic,O
heart,O
disease,PERCENT
%,PERCENT
with,O
obesity,PERCENT
%,PERCENT
with,O
rheumatoid,O
arthritis,PERCENT
%,PERCENT
with,O
stroke,CAUSE_OF_DEATH
or,O
transient,O
ischemic,O
attack,PERCENT
%,PERCENT
using,O
tobacco,CAUSE_OF_DEATH
Average,O
PM2,O
.5,NUMBER
(,O
g,O
/,O
m3,O
),O
Average,O
summer,DATE
temperature,O
(,O
K,O
),O
Average,O
summer,DATE
humidity,O
Average,O
winter,DATE
temperature,O
(,O
K,O
),O
Aver,O
‐,O
age,O
winter,DATE
humidity,O
Median,MISC
age,PERCENT
%,PERCENT
of,O
people,O
65,DURATION
years,DURATION
of,O
age,O
Sex,O
ratio,O
(,O
males,O
per,O
100,NUMBER
females,O
),O
Child,O
dependency,O
ratio,O
%,O
Island,O
na,O
‐,O
tive,PERCENT
%,PERCENT
two,NUMBER
or,O
more,O
races,O
related,O
metrics,O
used,O
in,O
the,O
analyses,O
.,O
Data,O
are,O
presented,O
overall,O
and,O
stratified,O
by,O
counties,O
with,O
vacci,O
‐,O
nation,O
coverage,O
below,O
and,O
above,O
the,O
Influenza,CAUSE_OF_DEATH
vaccination,O
and,O
COVID19,O
mortality,O
Primary,O
analyses,O
.,O
Several,O
variables,O
had,O
a,O
sig,O
‐,O
nificant,O
effect,O
on,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
.,O
including,O
de,O
‐,O
mographic,O
factors,O
like,O
the,O
race,O
and,O
education,O
level,O
.,O
together,O
with,O
a,O
number,O
of,O
chronic,O
health,O
conditions,O
like,O
diabetes,CAUSE_OF_DEATH
and,O
hy,O
‐,O
pertension,O
(,O
see,O
factor,O
after,O
stratification,O
into,O
quintiles,O
.,O
Such,O
generalized,O
linear,O
model,TITLE
produced,O
a,O
significant,O
negative,O
coeffi,O
‐,O
cient,O
for,O
influenza,CAUSE_OF_DEATH
after,O
controlling,O
for,O
confounding,O
variables,O
that,O
could,O
affect,O
both,O
the,O
proportion,O
of,O
vaccinated,O
individuals,O
and,O
mortality,O
in,O
an,O
rates,O
.,O
Specifically,O
.,O
for,O
every,O
10,PERCENT
%,PERCENT
increase,O
in,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
.,O
there,O
is,O
a,O
28,PERCENT
%,PERCENT
decrease,O
in,O
the,O
rate,O
of,O
mortality,O
being,O
stronger,O
in,O
the,O
counties,O
where,O
the,O
vacci,O
‐,O
nation,O
coverage,O
is,O
higher,O
.,O
Indeed,O
.,O
when,O
we,O
analyzed,O
the,O
link,O
be,O
‐,O
tween,O
vaccination,O
coverage,O
and,O
COVID,O
‐,O
19,NUMBER
mortality,O
within,O
each,O
US,COUNTRY
county,O
group,O
as,O
defined,O
by,O
the,O
propensity,O
score,O
quintiles,O
.,O
the,O
effect,O
was,O
from,O
COVID,O
‐,O
19,NUMBER
associated,O
with,O
a,O
10,PERCENT
%,PERCENT
increase,O
in,O
vacci,O
‐,O
nation,O
coverage,O
.,O
Results,O
shown,O
are,O
for,O
the,O
primary,O
analysis,O
per,O
‐,O
formed,O
on,O
all,O
counties,O
with,O
more,O
than,O
10,NUMBER
cases,O
.,O
and,O
for,O
the,DATE
sec,DATE
‐,O
ondary,O
analyses,O
where,O
distinct,O
thresholds,O
for,O
inclusion,O
where,O
used,O
(,O
respectively,O
.,O
more,O
than,O
50,NUMBER
and,O
100,NUMBER
confirmed,O
cases,O
),O
.,O
Vac,O
‐,O
cination,O
effect,O
Corrected,O
by,O
PS,O
quintiles,O
Corrected,O
by,O
continuous,O
PS,O
Corrected,O
by,O
PS,O
quintiles,O
and,O
US,COUNTRY
state,O
(,O
fixed,O
effects,O
),O
Cor,O
‐,O
rected,O
by,O
PS,O
quintiles,O
and,O
US,COUNTRY
state,O
(,O
mixed,O
effects,O
),O
study,O
.,O
Ef,O
‐,O
fects,O
are,O
reported,O
for,O
all,O
models,O
fitted,O
to,O
capture,O
the,O
link,O
be,O
‐,O
tween,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
and,O
COVID,O
mortality,O
in,O
the,O
US,COUNTRY
.,O
Each,O
line,O
represents,O
a,O
distinct,O
model,TITLE
type,O
or,O
adjust,O
‐,O
ment.Vaccination,O
refers,O
to,O
county,O
‐,O
level,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
in,O
people,O
>,O
=,O
65,DURATION
years,DURATION
.,O
PS,O
refers,O
to,O
vaccination,O
propen,O
‐,O
sity,O
score,O
.,O
All,O
the,O
models,O
are,O
quasi,O
‐,O
Poisson,PERSON
with,O
t,O
‐,O
statistic,O
.,O
with,O
exception,O
of,O
the,O
mixed,O
effects,O
one,NUMBER
which,O
is,O
a,O
Poisson,O
model,TITLE
with,O
Z,O
‐,O
score,O
statistic,O
.,O
Secondary,O
analyses,O
.,O
We,O
further,O
evaluated,O
the,O
robustness,O
of,O
this,O
effect,O
using,O
alternative,O
approaches,O
.,O
In,O
‐,O
cluding,O
the,O
propensity,O
score,O
as,O
a,O
linear,O
term,O
in,O
the,O
quasi,O
‐,O
Pois,O
‐,O
son,O
model,TITLE
yielded,O
similar,O
results,O
(,O
estimate,O
=,O
5.65,NUMBER
.,O
t,O
=,O
4.66,NUMBER
.,O
p,O
<,O
0.01,NUMBER
.,O
d,O
f,O
=,O
2031,DATE
.,O
access,O
and,O
testing,O
policies,O
at,O
the,O
state,O
level,O
using,O
a,O
fixed,O
effects,O
model,TITLE
(,O
estimate,O
=,O
5.64,NUMBER
.,O
t,O
=,O
9.16,NUMBER
.,O
p,O
<,O
2e,O
16,NUMBER
.,O
d,O
f,O
=,O
2027,DATE
.,O
directly,O
as,O
described,O
in,O
the,O
methods,O
section,O
.,O
The,O
results,O
showed,O
that,O
the,O
effect,O
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
remained,O
significant,O
The,O
effect,O
of,O
vaccination,O
coverage,O
on,O
COVID,O
‐,O
19,NUMBER
mor,O
‐,O
tality,O
in,O
the,O
US,COUNTRY
was,O
not,O
significant,O
after,O
removing,O
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
state,O
from,O
the,O
analysis,O
(,O
estimate,O
=,O
0.26,NUMBER
.,O
t,O
=,O
0.406,NUMBER
.,O
p,O
=,O
0.69,NUMBER
.,O
d,O
f,O
=,O
1975,DATE
),O
but,O
it,O
was,O
significant,O
when,O
adjusting,O
for,O
propensity,O
score,O
By,O
repeating,O
our,O
analysis,O
including,O
only,O
the,O
counties,O
with,O
at,O
least,O
one,NUMBER
death,O
.,O
the,O
effect,O
of,O
vaccination,O
remained,O
signifi,O
‐,O
cant,O
indicating,O
that,O
it,O
is,O
not,O
affected,O
by,O
the,O
counties,O
with,O
zero,NUMBER
mortality,O
(,O
estimate,O
=,O
3.10,NUMBER
.,O
t,O
=,O
2.51,NUMBER
.,O
p,O
=,O
0.01,NUMBER
.,O
d,O
f,O
=,O
1556,DATE
),O
.,O
Fi,O
‐,O
nally,O
.,O
increased,O
air,O
levels,O
of,O
particulate,O
matter,O
(,O
PM2,O
.5,NUMBER
),O
was,O
found,O
to,O
be,O
associated,O
with,O
a,O
higher,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
(,O
estimate,O
=,O
0.09,NUMBER
.,O
t,O
=,O
3.33,NUMBER
.,O
p,O
<,O
0.01,NUMBER
.,O
d,O
f,O
=,O
2028,DATE
),O
.,O
as,O
previously,DATE
reported24,O
.,O
Overall,O
.,O
the,O
results,O
from,O
all,O
these,O
analyses,O
were,O
consistent,O
.,O
further,O
confirming,O
that,O
the,O
link,O
be,O
‐,O
tween,O
influenza,CAUSE_OF_DEATH
vaccination,O
and,O
reduced,O
mortality,O
from,O
COVID,O
‐,O
19,NUMBER
is,O
robust,O
.,O
The,O
main,O
motivation,O
for,O
our,O
study,O
was,O
to,O
gather,O
pre,O
‐,O
liminary,O
evidence,O
about,O
a,O
possible,O
connection,O
between,O
influenza,CAUSE_OF_DEATH
vaccination,O
in,O
the,O
elderly,O
population,O
and,O
the,O
risk,O
of,O
mortality,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
On,O
one,NUMBER
hand,O
.,O
seasonal,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
is,O
asso,O
‐,O
ciated,O
with,O
the,O
development,O
of,O
several,O
respiratory,O
complications,CAUSE_OF_DEATH
.,O
especially,O
in,O
the,O
elderly14,O
.,O
On,O
the,O
other,O
hand,O
.,O
a,O
recent,O
report,O
points,O
to,O
increased,O
odds,O
of,O
non,O
‐,O
SARS,O
coronaviruses,O
infections,CAUSE_OF_DEATH
among,O
army,O
personnel,O
who,O
received,O
influenza,CAUSE_OF_DEATH
vaccination21,O
.,O
This,O
acquired,O
by,O
natural,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
.,O
which,O
would,O
protect,O
against,O
infection,CAUSE_OF_DEATH
by,O
other,O
viruses32,O
.,O
33,NUMBER
.,O
Public,O
county,O
‐,O
level,O
data,O
in,O
the,O
U.S.A.,COUNTRY
provide,O
a,O
platform,O
to,O
begin,O
exploring,O
this,O
is,O
‐,O
sue,O
.,O
We,O
quantified,O
the,O
county,O
‐,O
level,O
association,O
between,O
influenza,CAUSE_OF_DEATH
vaccine,O
coverage,O
in,O
people,O
older,O
than,O
65,DURATION
years,DURATION
and,O
COVID,O
‐,O
19,NUMBER
‐,O
re,O
‐,O
lated,O
deaths,O
in,O
these,O
data,O
.,O
We,O
focused,O
on,O
people,O
aged,O
65,DURATION
years,DURATION
and,O
older,O
since,O
this,O
age,O
group,O
is,O
more,O
susceptible,O
to,O
influenza,CAUSE_OF_DEATH
complications,CAUSE_OF_DEATH
and,O
thus,O
annual,SET
influenza,CAUSE_OF_DEATH
vaccination,O
is,O
recommend,O
‐,O
ed,O
for,O
them,O
.,O
This,O
age,O
group,O
also,O
has,O
a,O
higher,O
mortality,O
rate,O
and,O
a,O
greater,O
risk,O
for,O
developing,O
severe,O
complications,CAUSE_OF_DEATH
from,O
COVID,O
‐,O
19,NUMBER
.,O
compared,O
to,O
the,O
younger,O
population10,O
.,O
In,O
our,O
analyses,O
.,O
we,O
con,O
‐,O
trolled,O
for,O
a,O
wide,O
array,O
of,O
potential,O
confounding,O
variables,O
.,O
in,O
‐,O
cluding,O
population,O
density,O
.,O
social,O
and,O
economic,O
variables,O
.,O
educa,O
‐,O
tion,O
.,O
chronic,O
medical,O
conditions,O
.,O
and,O
other,O
important,O
demographic,O
and,O
environmental,O
factors,O
.,O
Our,O
results,O
suggest,O
a,O
reduction,O
in,O
COVID,O
‐,O
19,NUMBER
mortality,O
associated,O
with,O
higher,O
influenza,CAUSE_OF_DEATH
vaccination,O
rates,O
in,O
the,O
elderly,O
population,O
.,O
Specifically,O
.,O
we,O
found,O
that,O
overall,O
.,O
a,O
10,PERCENT
%,PERCENT
increase,O
in,O
vaccination,O
coverage,O
was,O
associated,O
on,O
average,O
with,O
a,O
statistically,O
significant,O
28,PERCENT
%,PERCENT
decrease,O
in,O
the,O
COVID,O
‐,O
19,NUMBER
death,O
rate,O
.,O
Our,O
findings,O
suggest,O
that,O
influenza,CAUSE_OF_DEATH
vaccina,O
‐,O
tion,O
can,O
play,O
a,O
protective,O
role,O
in,O
COVID,O
‐,O
19,NUMBER
.,O
and,O
that,O
additional,O
confirmatory,O
studies,O
at,O
the,O
individual,O
level,O
are,O
urgently,O
needed,O
.,O
This,O
conclusion,O
is,O
robust,O
to,O
several,O
variations,O
of,O
our,O
analytical,O
techniques,O
.,O
We,O
varied,O
the,O
time,O
frame,O
considered,O
.,O
and,O
our,O
thresh,O
‐,O
old,O
for,O
inclusion,O
of,O
counties,O
with,O
low,O
exposure,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
We,O
also,O
investigated,O
systematically,O
several,O
variations,O
in,O
the,O
methodology,O
used,O
for,O
adjusting,O
for,O
potential,O
confounding,O
factors,O
.,O
Among,O
the,O
analyses,O
we,O
considered,O
is,O
complete,O
stratification,O
by,O
quintiles,O
of,O
the,O
propensity,O
score,O
.,O
This,O
analysis,O
provides,O
five,NUMBER
However,O
.,O
the,O
effects,O
within,O
the,O
strata,O
differ,O
.,O
with,O
groups,O
of,O
counties,O
with,O
higher,O
generalized,O
propensity,O
scores,O
manifesting,O
higher,O
effects,O
.,O
Our,O
propensity,O
score,O
reflect,O
a,O
large,O
number,O
of,O
potential,O
confounders,O
.,O
many,O
of,O
which,O
have,O
an,O
important,O
effect,O
.,O
Thus,O
.,O
further,O
analyses,O
are,O
needed,O
to,O
shed,O
light,O
on,O
the,O
potential,O
sources,O
of,O
this,O
heterogeneity,O
.,O
Generally,O
speaking,O
.,O
however,O
.,O
our,O
analysis,O
considers,O
COVID,O
‐,O
19,NUMBER
mortality,O
per,O
inhabitant,O
.,O
and,O
thus,O
it,O
is,O
possible,O
that,O
higher,O
county,O
‐,O
level,O
vaccination,O
rates,O
may,O
by,O
themselves,O
provide,O
control,O
of,O
mortality,O
via,O
herd,O
immunity,O
.,O
Our,O
area,O
‐,O
level,O
association,O
is,O
consistent,O
with,O
a,O
protective,O
effect,O
.,O
which,O
can,O
be,O
explained,O
by,O
the,O
vaccines,O
effect,O
of,O
reducing,O
the,O
rate,O
of,O
hospitalization,O
and,O
severe,O
pulmonary,O
complications,CAUSE_OF_DEATH
in,O
the,O
elderly,O
.,O
Evidence,O
suggests,O
that,O
the,O
vaccine,O
benefit,O
is,O
greater,O
in,O
people,O
with,O
high,O
‐,O
risk,O
respiratory,O
conditions,O
like,O
chronic,O
ob,O
‐,O
structive,O
pulmonary,O
disease34,O
and,O
asthma35,O
.,O
Furthermore,O
.,O
in,O
‐,O
fluenza,O
vaccination,O
was,O
found,O
to,O
have,O
a,O
protective,O
effect,O
against,O
cardiovascular,O
events36,O
.,O
confirming,O
previous,O
findings,O
that,O
linked,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
to,O
increased,O
rate,O
of,O
hospitalization,O
and,O
death,O
from,O
myocardial,O
infarction37,O
.,O
38,NUMBER
.,O
A,O
complementary,O
ex,O
‐,O
planation,O
for,O
a,O
putative,O
protective,O
effect,O
is,O
that,O
unvaccinated,O
individuals,O
are,O
at,O
risk,O
of,O
persistent,O
viral,O
infections,CAUSE_OF_DEATH
.,O
leading,O
to,O
a,O
decline,O
in,O
T,O
‐,O
cell,O
diversity,O
which,O
in,O
turn,O
impairs,O
the,O
immune,O
response,O
against,O
other,O
pathogens,O
including,O
SARS,O
‐,O
CoV,O
‐,O
239,NUMBER
.,O
40,NUMBER
.,O
In,O
‐,O
fluenza,O
vaccination,O
.,O
on,O
the,O
other,O
hand,O
.,O
does,O
not,O
induce,O
a,O
strong,O
.,O
virus,O
‐,O
specific,O
CD8,O
T,O
‐,O
cell,O
immune,O
response,O
.,O
as,O
seen,O
with,O
natural,O
infection41,O
.,O
42,NUMBER
.,O
and,O
while,O
this,O
is,O
considered,O
a,O
major,O
disadvan,O
‐,O
tage,O
of,O
inactivated,O
influenza,CAUSE_OF_DEATH
vaccines,O
.,O
it,O
may,O
be,O
beneficial,O
in,O
clearing,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
as,O
vaccinated,O
individuals,O
will,O
have,O
more,O
T,O
‐,O
cell,O
diversity,O
(,O
and,O
thus,O
Importantly,O
.,O
the,O
influenza,CAUSE_OF_DEATH
virus,O
has,O
been,O
shown,O
to,O
induce,O
apoptosis,O
and,O
impair,O
the,O
cytotoxic,O
effect,O
of,O
natural,O
killer,O
(,O
NK,O
),O
cells4345,O
.,O
ultimately,O
impairing,O
the,O
host,TITLE
immune,O
defense,O
mechanisms,O
against,O
other,O
pathogens,O
.,O
in,O
‐,O
cluding,O
potentially,O
SARS7,O
/,O
17,NUMBER
CoV,O
‐,O
2,NUMBER
.,O
especially,O
in,O
the,O
acute,O
phase,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
Additionally,O
.,O
consistently,O
unvaccinated,O
individu,O
‐,O
als,O
are,O
more,O
likely,O
to,O
have,O
a,O
higher,O
proportion,O
of,O
influenza,CAUSE_OF_DEATH
‐,O
spe,O
‐,O
cific,O
resident,O
memory,O
T,O
‐,O
cells,O
(,O
TRM,O
),O
in,O
their,O
lungs,O
.,O
which,O
are,O
highly,O
proliferative,O
and,O
highly,O
productive,O
of,O
inflammatory,O
cy,O
‐,O
tokines46,O
.,O
47,NUMBER
.,O
This,O
.,O
in,O
turn,O
.,O
might,O
be,O
associated,O
with,O
the,O
exag,O
‐,O
gerated,O
inflammatory,O
response,O
and,O
severe,O
Acute,O
Respiratory,O
Dis,O
‐,O
tress,O
Syndrome,O
(,O
ARDS,ORGANIZATION
),O
seen,O
in,O
some,O
COVID,O
‐,O
19,NUMBER
patients48,O
.,O
Further,O
‐,O
more,O
.,O
the,O
Influenza,CAUSE_OF_DEATH
A,O
virus,O
has,O
been,O
recently,DATE
shown,O
to,O
up,O
‐,O
regu,O
‐,O
late,O
ACE2,O
receptors,O
in,O
the,O
lung,O
alveolar,O
cells49,O
.,O
suggesting,O
that,O
a,O
recent,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
can,O
potentially,O
lead,O
to,O
more,O
severe,O
pulmonary,O
complications,CAUSE_OF_DEATH
from,O
COVID,O
‐,O
19,NUMBER
.,O
in,O
light,O
of,O
the,O
fact,O
that,O
these,O
same,O
receptors,O
are,O
used,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
for,O
cellu,O
‐,O
lar,O
entry,O
.,O
We,O
regard,O
ours,O
as,O
an,O
urgent,O
.,O
but,O
preliminary,O
.,O
study,O
and,O
acknowledge,O
several,O
limitations,O
.,O
Important,O
potentially,O
con,O
‐,O
founding,O
variables,O
include,O
the,O
socioeconomic,O
levels,O
.,O
quality,O
of,O
healthcare,O
.,O
and,O
the,O
lack,O
of,O
uniform,O
death,O
reporting,O
approaches,O
.,O
While,O
our,O
covariates,O
allow,O
to,O
control,O
for,O
some,O
of,O
these,O
confound,O
‐,O
ing,O
factors,O
.,O
more,O
systematic,O
and,O
accurate,O
data,O
collection,O
ap,O
‐,O
proaches,O
would,O
improve,O
the,O
reliability,O
of,O
analysis,O
such,O
as,O
ours,O
.,O
An,O
important,O
limitation,O
is,O
that,O
we,O
could,O
only,O
control,O
for,O
the,O
number,O
of,O
tests,O
performed,O
at,O
the,O
state,O
level,O
.,O
since,O
testing,O
data,O
were,O
not,O
available,O
for,O
each,O
county,O
.,O
Furthermore,O
.,O
testing,O
avail,O
‐,O
ability,O
and,O
recommendations,O
.,O
especially,O
in,O
the,O
initial,O
phase,O
of,O
the,O
pandemic,O
.,O
varied,O
between,O
states,O
.,O
We,O
tried,O
to,O
mitigate,O
this,O
issue,O
by,O
using,O
the,O
total,O
population,O
in,O
the,O
county,O
as,O
the,O
offset,O
in,O
our,O
models,O
.,O
rather,O
than,O
the,O
total,O
number,O
of,O
confirmed,O
cases,O
.,O
Since,O
the,O
number,O
of,O
performed,O
tests,O
can,O
have,O
an,O
important,O
impact,O
on,O
the,O
number,O
of,O
reported,O
cases,O
.,O
we,O
decided,O
not,O
to,O
explore,O
the,O
effect,O
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
on,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
reported,O
infection,CAUSE_OF_DEATH
rates,O
.,O
We,O
were,O
also,O
unable,O
to,O
stratify,O
and,O
analyze,O
COVID,O
‐,O
19,NUMBER
death,O
rate,O
by,O
age,O
group,O
.,O
because,O
this,O
information,O
was,O
not,O
available,O
.,O
Similarly,O
.,O
in,O
our,O
study,O
.,O
we,O
could,O
not,O
take,O
into,O
account,O
the,O
vari,O
‐,O
ability,O
in,O
vaccine,O
formulation,O
and,O
in,O
vaccine,O
efficacy,O
.,O
which,O
de,O
‐,O
pends,O
on,O
the,O
predominant,O
circulating,O
strains,O
.,O
because,O
this,O
kind,O
of,O
data,O
was,O
not,O
reported,O
.,O
Based,O
on,O
the,O
information,O
currently,DATE
available,O
.,O
it,O
is,O
unclear,O
whether,O
the,O
observed,O
negative,O
associa,O
‐,O
tion,O
with,O
COVID,O
‐,O
19,NUMBER
mortality,O
could,O
also,O
be,O
observed,O
also,O
if,O
we,O
considered,O
natural,O
influenza,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
as,O
the,O
exposure,O
.,O
and,O
whether,O
vaccinations,O
against,O
other,O
respiratory,O
pathogens,O
or,O
other,O
diseases,CAUSE_OF_DEATH
can,O
confer,O
any,O
protection,O
.,O
In,O
this,O
regard,O
.,O
it,O
was,O
re,O
‐,O
cently,O
proposed,O
that,O
live,O
attenuated,O
vaccines,O
.,O
by,O
stimulating,O
the,O
innate,O
immunity,O
.,O
could,O
provide,O
transient,O
protection,O
against,O
COVID,O
‐,O
1950,DATE
.,O
It,O
is,O
also,O
important,O
to,O
underscore,O
that,O
COVID,O
‐,O
19,DATE
may,DATE
be,O
accompanied,O
by,O
innate,O
immune,O
response,O
suppression51,O
.,O
there,O
‐,O
fore,O
further,O
suggesting,O
that,O
vaccination,O
could,O
also,O
be,O
benefi,O
‐,O
cial,O
.,O
by,O
boosting,O
innate,O
immunity,O
.,O
Finally,O
.,O
an,O
important,O
poten,O
‐,O
tial,O
confounder,O
not,O
captured,O
in,O
our,O
dataset,O
concerns,O
the,O
use,O
of,O
other,O
drugs,CRIMINAL_CHARGE
.,O
Recent,O
studies,O
have,O
proposed,O
a,O
potential,O
effect,O
of,O
some,O
drugs,CRIMINAL_CHARGE
including,O
statins,O
and,O
anti,O
‐,O
hypertensives,O
like,O
ACEIs,O
/,O
ARBs,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
in,O
the,O
elderly,O
population52,O
;,O
however,O
.,O
these,O
potential,O
effects,O
are,O
still,O
not,O
confirmed,O
and,O
need,O
further,O
investigation,O
.,O
Although,O
many,O
important,O
confounding,O
vari,O
‐,O
ables,O
have,O
been,O
taken,O
into,O
account,O
in,O
our,O
analyses,O
.,O
there,O
is,O
still,O
a,O
strong,O
need,O
to,O
go,O
beyond,O
aggregated,O
data,O
to,O
perform,O
analyses,O
at,O
the,O
individual,O
level,O
.,O
These,O
studies,O
would,O
provide,O
much,O
more,O
robust,O
evidence,O
of,O
a,O
possible,O
protective,O
effect,O
of,O
in,O
‐,O
fluenza,O
vaccination,O
on,O
COVID,O
‐,O
19,NUMBER
mortality,O
.,O
and,O
also,O
help,O
deter,O
‐,O
mine,O
the,O
underlying,O
biological,O
If,O
an,O
effect,O
consistent,O
with,O
our,O
analysis,O
was,O
confirmed,O
in,O
individual,O
level,O
analyses,O
.,O
it,O
would,O
justify,O
a,O
more,O
aggressive,O
and,O
targeted,O
influenza,CAUSE_OF_DEATH
vaccination,O
pol,O
‐,O
icy,O
in,O
the,O
elderly,O
population,O
and,O
their,O
caregivers,O
.,O
to,O
reduce,O
the,O
rates,O
of,O
hospitalization,O
.,O
severe,O
respiratory,O
complications,CAUSE_OF_DEATH
.,O
and,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
This,O
would,O
be,O
of,O
paramount,O
importance,O
given,O
the,O
paucity,O
of,O
effective,O
treatment,O
or,O
vaccine,O
for,O
COVID,O
‐,O
19,NUMBER
and,O
the,O
extreme,O
pressure,O
on,O
healthcare,O
systems,O
.,O
1,NUMBER
.,O
Max,PERSON
Roser,PERSON
.,O
H.,PERSON
R.,PERSON
&,O
Ortiz,PERSON
‐,PERSON
Ospina,PERSON
.,O
E.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
(,O
covid,O
‐,O
19,NUMBER
),O
statistics,O
and,O
research,O
.,O
Our,O
World,MISC
Data,MISC
(,O
2020,DATE
),O
.,O
Early,O
transmission,O
dynamics,O
in,O
wuhan,O
.,O
china,COUNTRY
.,O
of,O
novel,O
coronavirusinfected,O
pneumonia,CAUSE_OF_DEATH
.,O
2,NUMBER
.,O
Li,PERSON
.,O
Q.,O
et,O
al,O
.,O
3,NUMBER
.,O
Rothe,PERSON
.,O
C.,O
et,O
al,O
.,O
Transmission,O
of,O
2019,DATE
‐,O
ncov,O
infection,CAUSE_OF_DEATH
from,O
an,O
asymptomatic,O
contact,O
in,O
germany,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
382,NUMBER
.,O
4,NUMBER
.,O
Yu,PERSON
.,O
P.,O
.,O
Zhu,PERSON
.,O
J.,O
.,O
Zhang,PERSON
.,O
Z.,O
.,O
Han,O
.,O
Y.,O
&,O
Huang,PERSON
.,O
L,O
.,O
A,O
familial,O
cluster,O
of,O
infection,CAUSE_OF_DEATH
associated,O
with,O
the,O
2019,DATE
novel,O
coronavirus,O
5,NUMBER
.,O
Wu,PERSON
.,O
Z.,O
&,O
McGoogan,PERSON
.,O
J.,PERSON
M.,PERSON
Characteristics,PERSON
of,O
and,O
Important,O
Lessons,O
From,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Outbreak,O
in,O
China,COUNTRY
:,O
Summary,O
of,O
a,O
Report,O
of,O
72314,NUMBER
Cases,O
From,O
the,O
Chinese,NATIONALITY
Center,O
for,O
Disease,CAUSE_OF_DEATH
Con,O
‐,O
trol,O
and,O
Prevention,O
.,O
6,NUMBER
.,O
Guan,O
.,O
W.,O
‐,O
J.,O
et,O
al,O
.,O
Clinical,O
characteris,O
‐,O
tics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
china,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
382,NUMBER
.,O
17081720,NUMBER
(,O
2020,DATE
),O
.,O
7,NUMBER
.,O
Wang,PERSON
.,O
D.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
138,NUMBER
hospitalized,O
patients,O
with,O
2019,DATE
novel,O
coronavirus,O
‐,O
infected,O
pneumonia,CAUSE_OF_DEATH
in,O
wuhan,O
.,O
china,COUNTRY
.,O
JAMA,O
323,NUMBER
.,O
10611069,NUMBER
(,O
2020,DATE
),O
.,O
8,NUMBER
.,O
Huang,PERSON
.,O
C.,O
et,O
al,O
.,O
Clinical,O
features,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coronavirus,O
in,O
wuhan,O
.,O
china,COUNTRY
.,O
Lancet,O
395,NUMBER
.,O
497506,NUMBER
9,NUMBER
.,O
Lechien,PERSON
.,O
J.,PERSON
R.,PERSON
et,O
al,O
.,O
Olfactory,O
and,O
gustatory,O
dysfunctions,O
as,O
a,O
clinical,O
presen,O
‐,O
tation,O
of,O
mild,O
‐,O
to,O
‐,O
moderate,O
forms,O
of,O
the,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
covid,O
‐,O
19,NUMBER
),O
:,O
a,O
multicenter,O
european,NATIONALITY
study,O
.,O
Eur,O
Arch,O
Otorhinolaryn,O
‐,O
gol,O
111,NUMBER
(,O
2020,DATE
),O
.,O
10,NUMBER
.,O
Zhou,PERSON
.,O
F.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
risk,O
factors,O
for,O
mortality,O
of,O
adult,O
inpatients,O
with,O
covid,O
‐,O
19,NUMBER
in,O
wuhan,O
.,O
china,COUNTRY
:,O
a,O
retrospective,O
cohort,O
study,O
.,O
Lancet,O
395,NUMBER
.,O
10541062,NUMBER
(,O
2020,DATE
),O
.,O
11,NUMBER
.,O
Richardson,PERSON
.,O
S.,O
et,O
al,O
.,O
Presenting,O
characteristics,O
.,O
comorbidi,O
‐,O
ties,O
.,O
and,O
outcomes,O
among,O
5700,NUMBER
patients,O
hospitalized,O
with,O
covid,O
‐,O
19,NUMBER
in,O
the,O
new,O
york,O
city,O
area,O
.,O
JAMA,O
e206775,O
(,O
2020,DATE
),O
.,O
12,NUMBER
.,O
Xing,PERSON
.,O
Q.,O
et,O
al,O
.,O
Precautions,O
are,O
needed,O
for,O
covid,O
‐,O
19,NUMBER
patients,O
with,O
coinfection,O
of,O
common,O
respiratory,O
pathogens,O
.,O
medRxiv,O
14,NUMBER
.,O
Keilman,PERSON
.,O
L.,PERSON
J.,PERSON
Sea,PERSON
‐,O
sonal,O
influenza,CAUSE_OF_DEATH
(,O
flu,CAUSE_OF_DEATH
),O
.,O
Nurs,O
.,O
Clin,PERSON
.,O
North,O
Am,O
.,O
54,NUMBER
.,O
227,NUMBER
243,NUMBER
(,O
2019,DATE
),O
.,O
15,NUMBER
.,O
Hak,PERSON
.,O
E.,O
et,O
al,O
.,O
Influence,O
of,O
High,O
‐,O
Risk,O
Medical,O
Conditions,O
on,O
the,O
Effectiveness,O
of,O
Influenza,CAUSE_OF_DEATH
Vaccination,O
among,O
Elderly,O
Members,O
of,O
3,NUMBER
Large,O
Managed,O
‐,O
Care,O
Organizations,O
.,O
Clin,PERSON
.,O
Infect,O
.,O
Dis,O
.,O
35,NUMBER
.,O
370377,NUMBER
(,O
2002,DATE
),O
.,O
16,NUMBER
.,O
Fry,O
.,O
A.,O
M.,O
et,O
al,O
.,O
Modeling,O
the,O
effect,O
of,O
dif,O
‐,O
ferent,O
vaccine,O
effectiveness,O
estimates,O
on,O
the,O
number,O
of,O
vaccine,O
‐,O
prevented,O
influenza,CAUSE_OF_DEATH
‐,O
associated,O
hospitalizations,O
in,O
older,O
adults,O
.,O
Clin,O
Infect,O
Dis,O
59,NUMBER
.,O
406409,NUMBER
(,O
2014,DATE
),O
.,O
17,NUMBER
.,O
Nichol,PERSON
.,O
K.,PERSON
L.,PERSON
.,O
Baken,LOCATION
.,O
L.,O
&,O
Nelson,PERSON
.,O
A.,O
Relation,O
between,O
influenza,CAUSE_OF_DEATH
vaccination,O
and,O
outpa,O
‐,O
tient,O
visits,O
.,O
hospitalization,O
.,O
and,O
mortality,O
in,O
elderly,O
persons,O
with,O
chronic,O
lung,O
disease,CAUSE_OF_DEATH
.,O
Ann,MISC
Intern,TITLE
Med,MISC
130,NUMBER
.,O
397403,NUMBER
(,O
1999,DATE
),O
.,O
18,NUMBER
.,O
Taksler,PERSON
.,O
G.,PERSON
B.,PERSON
.,O
Rothberg,PERSON
.,O
M.,ORGANIZATION
B.,ORGANIZATION
&,ORGANIZATION
Cutler,ORGANIZATION
.,O
D.,PERSON
M.,PERSON
Association,PERSON
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
in,O
younger,O
adults,O
with,O
influen,O
‐,O
za,O
‐,O
related,O
illness,CAUSE_OF_DEATH
in,O
the,O
elderly,O
.,O
Clin,O
Infect,O
Dis,O
61,NUMBER
.,O
14951503,NUMBER
(,O
2015,DATE
),O
.,O
19,NUMBER
.,O
Wilder,PERSON
‐,PERSON
Smith,PERSON
.,O
A.,O
&,O
Freedman,O
.,O
D.,O
O.,O
Isolation,O
.,O
quar,O
‐,O
antine,O
.,O
social,O
distancing,O
and,O
community,O
containment,O
:,O
pivotal,O
role,O
20,NUMBER
.,O
Matrajt,O
.,O
L.,ORGANIZATION
&,ORGANIZATION
Leung,ORGANIZATION
.,O
T.,O
Evaluating,O
the,O
effectiveness,O
of,O
so,O
‐,O
cial,O
distancing,O
interventions,O
to,O
delay,O
or,O
flatten,O
the,O
epidemic,O
21,NUMBER
.,O
Wolff,PERSON
.,O
G.,PERSON
G.,PERSON
Influenza,PERSON
vaccination,O
and,O
respiratory,O
virus,O
in,O
‐,O
terference,O
among,O
department,O
of,O
defense,O
personnel,O
during,O
the,O
20172018,NUMBER
influenza,CAUSE_OF_DEATH
season,O
.,O
Vaccine,O
38,NUMBER
.,O
350,NUMBER
354,NUMBER
(,O
2020,DATE
),O
.,O
23,NUMBER
.,O
Hy,PERSON
‐,PERSON
attsville,O
.,O
M.,PERSON
National,PERSON
center,O
for,O
health,O
statistics,O
.,O
guidance,O
for,O
certifying,O
deaths,O
due,O
to,O
covid19,O
.,O
available,O
from,O
24,NUMBER
.,O
Wu,PERSON
.,O
X.,O
.,O
Nethery,PERSON
.,O
R.,O
C.,O
.,O
Sabath,PERSON
.,O
B.,O
M.,O
.,O
Braun,LOCATION
.,O
D.,O
&,O
Dominici,PERSON
.,O
F.,O
Exposure,O
to,O
air,O
pollution,O
and,O
COVID,O
‐,O
19,NUMBER
mortality,O
in,O
Harbor,O
Laboratory,O
Press,O
.,O
R.,MISC
&,MISC
Gentleman,MISC
.,O
R,O
:,O
A,O
Language,O
for,O
JOURNAL,O
OF,O
COMPUTATION,O
‐,O
AL,STATE_OR_PROVINCE
AND,O
GRAPHICAL,O
STATISTICS,O
(,O
1996,DATE
),O
.,O
26,NUMBER
.,O
R,PERSON
Core,PERSON
Team,PERSON
.,O
R,O
:,O
A,O
Lan,O
‐,O
guage,O
and,O
Environment,ORGANIZATION
for,ORGANIZATION
Statistical,ORGANIZATION
Computing,ORGANIZATION
.,O
R,O
Foundation,O
for,O
Statistical,O
Computing,O
.,O
Vienna,CITY
.,O
29,NUMBER
.,O
ROSENBAUM,LOCATION
.,O
P.,ORGANIZATION
R.,ORGANIZATION
&,ORGANIZATION
RUBIN,ORGANIZATION
.,O
D.,O
B,O
.,O
The,O
central,O
role,O
of,O
the,O
propensity,O
score,O
in,O
observational,O
studies,O
for,O
causal,O
effects,O
.,O
30,NUMBER
.,O
Austin,CITY
.,O
P.,PERSON
C,PERSON
.,O
An,O
introduction,O
to,O
propensity,O
score,O
methods,O
for,O
reducing,O
the,O
effects,O
of,O
confounding,O
in,O
observational,O
studies,O
.,O
Multivar,O
.,O
Behav,O
Res,O
46,NUMBER
.,O
399424,NUMBER
(,O
2011,DATE
),O
.,O
31,NUMBER
.,O
Brookhart,PERSON
.,O
M.,O
A.,O
et,O
al,O
.,O
Variable,O
selection,O
for,O
propensity,O
score,O
models,O
.,O
Am,O
J,O
Epidemiol,O
163,NUMBER
.,O
11491156,NUMBER
(,O
2006,DATE
),O
.,O
32,NUMBER
.,O
SUZUKI,PERSON
.,O
M.,O
.,O
CAMACHO,LOCATION
.,O
A.,O
&,O
ARIYOSHI,O
.,O
K.,O
Potential,O
effect,O
of,O
virus,O
inter,O
‐,O
ference,O
on,O
influenza,CAUSE_OF_DEATH
vaccine,O
effectiveness,O
estimates,O
in,O
test,O
‐,O
neg,O
‐,O
ative,O
designs,O
.,O
Epidemiol,O
.,O
Infect,O
.,O
142,NUMBER
.,O
26422646,NUMBER
(,O
2014,DATE
),O
.,O
33,NUMBER
.,O
Cowling,O
.,O
B.,PERSON
J.,PERSON
et,O
al,O
.,O
Increased,O
Risk,O
of,O
Noninfluenza,O
Respiratory,O
Virus,O
Infections,CAUSE_OF_DEATH
Associated,O
With,O
Receipt,O
of,O
Inactivated,O
Influenza,CAUSE_OF_DEATH
Vaccine,O
.,O
Clin,PERSON
.,O
Infect,O
.,O
Dis,O
.,O
54,NUMBER
.,O
17781783,NUMBER
(,O
2012,DATE
),O
.,O
BMC,O
Pulm,O
Med,O
17,NUMBER
.,O
79,NUMBER
(,O
2017,DATE
),O
.,O
36,NUMBER
.,O
Udell,PERSON
.,O
J.,O
A.,O
et,O
al,O
.,O
Association,O
between,O
in,O
‐,O
fluenza,O
vaccination,O
and,O
cardiovascular,O
outcomes,O
in,O
high,O
‐,O
risk,O
pa,O
‐,O
tients,O
:,O
a,O
meta,O
‐,O
analysis,O
.,O
JAMA,O
310,NUMBER
.,O
17111720,NUMBER
(,O
2013,DATE
),O
.,O
37,NUMBER
.,O
Warren,PERSON
‐,PERSON
Gash,O
.,O
C.,O
et,O
al,O
.,O
Circulating,O
influenza,CAUSE_OF_DEATH
virus,O
.,O
climatic,O
factors,O
.,O
and,O
acute,O
myocardial,CAUSE_OF_DEATH
infarction,CAUSE_OF_DEATH
:,O
a,O
time,O
series,O
study,O
in,O
england,COUNTRY
and,O
wales,O
and,O
hong,O
kong,O
.,O
J,O
Infect,O
Dis,O
203,NUMBER
.,O
17101718,NUMBER
(,O
2011,DATE
),O
.,O
38,NUMBER
.,O
Madjid,PERSON
.,O
M.,O
et,O
al,O
.,O
Influenza,CAUSE_OF_DEATH
epidemics,O
and,O
acute,O
respiratory,O
dis,O
‐,O
ease,O
activity,O
are,O
associated,O
with,O
a,O
surge,O
in,O
autopsy,O
‐,O
confirmed,O
coronary,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
death,O
:,O
results,O
from,O
8,DURATION
years,DURATION
of,O
autopsies,O
in,O
34.892,NUMBER
subjects,O
.,O
Eur,O
Hear,O
.,O
J,O
28,NUMBER
.,O
12051210,NUMBER
(,O
2007,DATE
),O
.,O
39,NUMBER
.,O
Lam,O
‐,O
bert,O
.,O
N.,O
D.,O
.,O
Ovsyannikova,LOCATION
.,O
I.,O
G.,O
.,O
Pankratz,PERSON
.,O
V.,O
S.,O
.,O
Jacobson,PERSON
.,O
R.,O
M.,O
&,O
Poland,COUNTRY
.,O
G.,PERSON
A.,PERSON
Understanding,PERSON
the,O
immune,O
response,O
40,NUMBER
.,O
Channap,O
‐,O
panavar,O
.,O
R.,O
et,O
al,O
.,O
Dysregulated,O
type,O
i,NUMBER
interferon,O
and,O
inflammato,O
‐,O
ry,O
monocyte,O
‐,O
macrophage,O
responses,O
cause,O
lethal,O
pneumonia,CAUSE_OF_DEATH
in,O
sars,O
‐,O
cov,O
‐,O
infected,O
mice,O
.,O
Cell,O
Host,TITLE
Microbe,O
19,NUMBER
.,O
181193,NUMBER
(,O
2016,DATE
),O
.,O
41,NUMBER
.,O
Grant,PERSON
.,O
E.,PERSON
J.,PERSON
et,O
al,O
.,O
Broad,O
cd8,O
(,O
+,O
),O
t,O
cell,O
cross,O
‐,O
recognition,O
of,O
dis,O
‐,O
tinct,O
influenza,CAUSE_OF_DEATH
a,O
strains,O
in,O
humans,O
.,O
Nat,ORGANIZATION
Commun,ORGANIZATION
9,NUMBER
.,O
5427,NUMBER
42,NUMBER
.,O
McEl,O
‐,O
haney,O
.,O
J.,PERSON
E.,PERSON
et,O
al,O
.,O
The,O
immune,O
response,O
to,O
influenza,CAUSE_OF_DEATH
in,O
older,O
hu,O
‐,O
mans,O
:,O
beyond,O
immune,O
senescence,O
.,O
Immun,O
.,O
&,O
ageing,O
:,O
I,O
&,O
A,O
17,NUMBER
.,O
1010,DATE
(,O
2020,DATE
),O
.,O
43,NUMBER
.,O
Mao,PERSON
.,O
H.,O
et,O
al,O
.,O
Inhibition,O
of,O
human,O
natural,O
killer,O
cell,O
activity,O
by,O
influenza,CAUSE_OF_DEATH
virions,O
and,O
hemagglutinin,O
.,O
J.,O
virology,O
84,NUMBER
.,O
44,NUMBER
.,O
Mao,PERSON
.,O
H.,O
et,O
al,O
.,O
Influenza,CAUSE_OF_DEATH
virus,O
directly,O
infects,O
human,O
natural,O
killer,O
cells,O
and,O
induces,O
cell,O
apoptosis,O
.,O
J.,O
virology,O
83,NUMBER
.,O
45,NUMBER
.,O
Denney,PERSON
.,O
L.,O
et,O
al,O
.,O
Reduction,O
of,O
natural,O
killer,O
but,O
not,O
effec,O
‐,O
tor,O
cd8,O
t,O
lymphocytes,O
in,O
three,NUMBER
consecutive,O
cases,O
of,O
severe,O
/,O
lethal,O
h1n1,O
/,O
09,NUMBER
influenza,CAUSE_OF_DEATH
a,O
virus,O
infection,CAUSE_OF_DEATH
.,O
PLoS,O
One,NUMBER
5,NUMBER
.,O
e10675,O
(,O
2010,DATE
),O
.,O
46,NUMBER
.,O
Purwar,O
.,O
R.,O
et,O
al,O
.,O
Resident,O
memory,O
t,O
cells,O
(,O
t,O
(,O
rm,O
),O
),O
are,O
abun,O
‐,O
dant,O
in,O
human,O
lung,O
:,O
diversity,O
.,O
function,O
.,O
and,O
antigen,O
specificity,O
.,O
PloS,O
one,NUMBER
6,NUMBER
.,O
e16245e16245,NUMBER
(,O
2011,DATE
),O
.,O
47,NUMBER
.,O
Pizzolla,PERSON
.,O
A.,O
et,O
al,O
.,O
In,O
‐,O
fluenza,O
‐,O
specific,O
lung,O
‐,O
resident,O
memory,O
t,O
cells,O
are,O
proliferative,O
and,O
polyfunctional,O
and,O
maintain,O
diverse,O
tcr,O
profiles,O
.,O
The,O
J.,O
clinical,O
investigation,O
128,NUMBER
.,O
721733,NUMBER
(,O
2018,DATE
),O
.,O
48,NUMBER
.,O
Henderson,PERSON
.,O
L.,PERSON
A.,PERSON
et,O
al,O
.,O
On,O
the,O
alert,O
for,O
cytokine,O
storm,CAUSE_OF_DEATH
:,O
Immunopathology,O
in,O
covid,O
‐,O
19,NUMBER
.,O
Arthritis,O
Rheumatol,O
(,O
2020,DATE
),O
.,O
49,NUMBER
.,O
Hui,O
.,O
K.,PERSON
P.,PERSON
Y.,PERSON
et,O
al,O
.,O
Tropism,O
.,O
replication,O
competence,O
.,O
and,O
innate,O
immune,O
responses,O
of,O
the,O
coronavirus,O
sars,O
‐,O
cov,O
‐,O
2,NUMBER
in,O
50,NUMBER
.,O
Chumakov,PERSON
.,O
K.,O
.,O
Benn,PERSON
.,O
C.,O
S.,O
.,O
Aa,O
‐,O
by,O
.,O
P.,O
.,O
Kottilil,LOCATION
.,O
S.,O
&,O
Gallo,PERSON
.,O
R.,O
Can,O
existing,O
live,O
vaccines,O
pre,O
‐,O
vent,O
covid,O
‐,O
19,NUMBER
?,O
Science,O
368,NUMBER
.,O
51,NUMBER
.,O
Zheng,PERSON
.,O
M.,O
et,O
al,O
.,O
Functional,O
ex,O
‐,O
haustion,O
of,O
antiviral,O
lymphocytes,O
in,O
covid,O
‐,O
19,NUMBER
patients,O
.,O
Cell,O
Mol,O
Immunol,ORGANIZATION
17,NUMBER
.,O
533535,NUMBER
.,O
52,NUMBER
.,O
De,PERSON
Spiegeleer,PERSON
.,O
A.,O
et,O
al,O
.,O
The,O
effects,O
of,O
arbs,O
.,O
aceis,O
and,O
statins,O
on,O
clinical,O
outcomes,O
of,O
covid,O
‐,O
19,NUMBER
infec,O
‐,O
tion,O
among,O
nursing,O
home,O
residents,O
.,O
medRxiv,O
2020.05.11.20096347,NUMBER
(,O
2020,DATE
),O
.,O
This,O
publication,O
was,O
made,O
possible,O
through,O
support,O
from,O
the,O
NIH,ORGANIZATION
‐,O
NCI,ORGANIZATION
grants,O
P30CA006973,O
(,O
L.M.,LOCATION
),O
.,O
L.M.,PERSON
conceived,O
the,O
idea,O
of,O
the,O
study,O
.,O
CZ,O
wrote,O
the,O
code,O
used,O
to,O
aggregate,O
data,O
and,O
per,O
‐,O
form,O
analysis,O
.,O
G.P.,PERSON
conducted,O
the,O
first,ORDINAL
analysis,O
of,O
the,O
data,O
and,O
identified,O
the,O
appropriate,O
statistical,O
models,O
to,O
use,O
.,O
E.C.,O
inde,O
‐,O
pendently,O
validated,O
the,O
analysis,O
.,O
C.Z.,O
.,O
COVID,O
‐,O
19,NUMBER
data,O
up,O
to,O
June,DATE
10,NUMBER
.,O
2020,DATE
were,O
imported,O
using,O
the,O
JHU,O
repository,O
.,O
Since,O
this,O
repository,O
does,O
not,O
report,O
Rhode,STATE_OR_PROVINCE
Island,STATE_OR_PROVINCE
COVID,O
‐,O
19,NUMBER
‐,O
related,O
deaths,O
at,O
the,O
county,O
level,O
.,O
that,O
information,O
was,O
obtained,O
from,O
the,O
NYT,O
repository,O
instead,O
.,O
Counties,O
with,O
missing,O
information,O
regarding,O
the,O
variable,O
of,O
interest,O
or,O
the,O
confounders,O
as,O
well,O
as,O
those,O
with,O
less,O
then,O
10,NUMBER
cases,O
were,O
not,O
included,O
in,O
the,O
analysis,O
.,O
The,O
final,O
dataset,O
used,O
for,O
the,O
main,O
analysis,O
comprises,O
2034,NUMBER
counties,O
.,O
Shown,O
is,O
the,O
coefficients,O
and,O
95,PERCENT
%,PERCENT
CI,O
of,O
the,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
obtained,O
in,O
the,O
quasi,O
‐,O
Poisson,O
regression,O
analysis,O
as,O
a,O
function,O
of,O
together,O
.,O
From,O
each,O
cluster,O
.,O
we,O
chose,O
a,O
single,O
vari,O
‐,O
able,O
to,O
be,O
used,O
as,O
a,O
covariate,O
in,O
the,O
quasi,O
‐,O
Poisson,O
model,TITLE
in,O
the,O
direct,O
adjustment,O
approach,O
.,O
Family,O
households,O
Families,O
with,O
only,O
one,NUMBER
parent,O
With,O
bachelor,TITLE
degree,O
With,O
Internet,O
Ratio,O
of,O
hospital,O
beds,O
(,O
per,O
100.000,NUMBER
people,O
),O
Alzheimers,O
disease,CAUSE_OF_DEATH
Atrial,O
fibrillation,O
Breast,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
Colorectal,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
Lung,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
Chronic,O
obstructive,O
pulmonary,O
disease,CAUSE_OF_DEATH
Chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
Heart,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
Ischemic,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
Rheumatoid,O
arthritis,O
Tobacco,CAUSE_OF_DEATH
use,O
Median,MISC
income,O
Sum,O
‐,O
mer,O
temperature,O
Summer,DATE
humidity,O
Winter,DATE
temperature,O
Winter,DATE
humidi,O
‐,O
ty,O
Median,MISC
age,O
Sex,O
ratio,O
Child,O
dependency,O
Black,O
race,O
Latino,O
race,O
White,O
race,O
Asian,NATIONALITY
race,O
Island,O
native,O
race,O
Other,O
race,O
Two,NUMBER
or,O
more,O
races,O
Total,O
COVID,O
‐,O
19,NUMBER
tests,O
Days,DURATION
since,O
the,O
first,ORDINAL
case,O
variables,O
.,O
The,O
propensity,O
score,O
was,O
calculated,O
by,O
regressing,O
the,O
logit,O
of,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
on,O
the,O
selected,O
confounding,O
vari,O
‐,O
ables,O
.,O
Influenza,CAUSE_OF_DEATH
vaccination,O
in,O
people,O
>,O
=,O
65,DURATION
years,DURATION
regression,O
model,TITLE
using,O
the,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
outcome,O
variable,O
.,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
as,O
the,O
independent,RELIGION
vari,O
‐,O
able,O
.,O
and,O
adjusting,O
for,O
propensity,O
score,O
quintiles,O
.,O
Total,O
popula,O
‐,O
tion,O
was,O
used,O
as,O
offset,O
to,O
the,O
model,TITLE
.,O
Influenza,CAUSE_OF_DEATH
vaccination,O
in,O
people,O
>,O
=,O
65,DURATION
years,DURATION
Propensity,O
Score,O
quasi,O
‐,O
Poisson,O
regression,O
mod,O
‐,O
el,O
using,O
the,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
outcome,O
vari,O
‐,O
able,O
.,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
as,O
the,O
independent,RELIGION
variable,O
.,O
and,O
adjusting,O
for,O
propensity,O
score,O
as,O
continuous,O
variable,O
.,O
Total,O
population,O
was,O
used,O
as,O
offset,O
.,O
Influenza,CAUSE_OF_DEATH
vaccination,O
in,O
people,O
>,O
=,O
65,DURATION
years,DURATION
the,O
number,O
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
outcome,O
variable,O
.,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
as,O
the,O
independent,RELIGION
vari,O
‐,O
able,O
.,O
adjusting,O
for,O
propensity,O
score,O
quintiles,O
.,O
and,O
controlling,O
for,O
State,O
differences,O
using,O
fixed,O
effect,O
model,TITLE
.,O
Influenza,CAUSE_OF_DEATH
vacci,O
‐,O
nation,O
in,O
people,O
>,O
=,O
65,DURATION
years,DURATION
of,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
as,O
the,O
out,O
‐,O
come,O
variable,O
.,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
as,O
the,O
independent,RELIGION
variable,O
.,O
adjusting,O
for,O
propensity,O
score,O
quintiles,O
.,O
and,O
control,O
‐,O
ling,O
for,O
State,O
differences,O
by,O
including,O
State,ORGANIZATION
as,O
a,O
random,O
factor,O
.,O
1st,ORDINAL
Quintile,O
Intercept,O
1st,ORDINAL
Quintile,O
Immunization,O
2nd,ORDINAL
Quintile,O
In,O
‐,O
tercept,O
2nd,ORDINAL
Quintile,O
Immunization,O
3rd,ORDINAL
Quintile,O
Intercept,O
3rd,ORDINAL
Quintile,O
Immunization,O
4th,ORDINAL
Quintile,O
Intercept,O
4th,ORDINAL
Quintile,O
Immu,O
‐,O
nization,O
5th,ORDINAL
Quintile,O
Intercept,O
5th,ORDINAL
Quintile,O
Immunization,MISC
strata,O
based,O
on,O
their,O
propensity,O
scores,O
quintile,O
.,O
Then,O
.,O
we,O
fit,O
a,O
quasi,O
‐,O
Poisson,PERSON
regression,O
in,O
each,O
stratum,O
using,O
the,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
deaths,O
as,O
the,O
outcome,O
and,O
influenza,CAUSE_OF_DEATH
vaccination,O
coverage,O
as,O
the,O
independent,RELIGION
variable,O
after,O
adjusting,O
for,O
the,O
propensity,O
score,O
.,O
Shown,O
is,O
the,O
intercept,O
and,O
coefficient,O
for,O
vaccination,O
coverage,O
from,O
the,O
quasi,O
‐,O
Poisson,PERSON
model,TITLE
in,O
each,O
stratum,O
.,O
Influenza,CAUSE_OF_DEATH
vaccina,O
‐,O
tion,O
(,O
>,O
10,NUMBER
cases,O
),O
Influenza,CAUSE_OF_DEATH
vaccination,O
(,O
>,O
50,NUMBER
cases,O
),O
Influenza,CAUSE_OF_DEATH
vaccination,O
(,O
>,O
100,NUMBER
cases,O
),O
Influenza,CAUSE_OF_DEATH
vaccination,O
(,O
without,O
New,O
York,O
),O
distinct,O
quasi,O
‐,O
Poisson,O
regressions,O
in,O
which,O
the,O
number,O
of,O
counties,O
included,O
varies,O
based,O
on,O
the,O
minimum,O
number,O
of,O
cases,O
.,O
or,O
in,O
which,O
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
State,LOCATION
counties,O
were,O
excluded,O
.,O
In,O
each,O
model,TITLE
.,O
the,O
number,O
of,O
COVID,O
‐,O
19,NUMBER
deaths,O
was,O
used,O
as,O
the,O
outcome,O
and,O
in,O
‐,O
fluenza,O
vaccination,O
coverage,O
in,O
people,O
>,O
=,O
65,NUMBER
together,O
with,O
propensity,O
score,O
(,O
continuous,O
),O
were,O
used,O
as,O
the,O
independent,RELIGION
vari,O
‐,O
ables,O
.,O
Total,O
population,O
was,O
used,O
as,O
Influenza,CAUSE_OF_DEATH
vaccination,O
in,O
peo,O
‐,O
ple,O
>,O
=,O
65,DURATION
years,DURATION
Family,O
households,O
Ratio,O
of,O
hospital,O
beds,O
(,O
per,O
1000,NUMBER
people,O
),O
Breast,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
Lung,CAUSE_OF_DEATH
cancer,CAUSE_OF_DEATH
Chronic,O
obstructive,O
pul,O
‐,O
monary,O
disease,CAUSE_OF_DEATH
Median,MISC
income,O
Summer,DATE
temperature,O
Summer,DATE
humidity,O
Winter,DATE
temperature,O
Winter,DATE
humidity,O
Sex,O
ratio,O
Days,DURATION
since,O
the,O
first,ORDINAL
case,O
We,O
clustered,O
the,O
42,NUMBER
candidate,TITLE
variables,O
based,O
on,O
their,O
cor,O
‐,O
relation,O
with,O
each,O
other,O
.,O
then,O
selected,O
only,O
one,NUMBER
variable,O
from,O
each,O
cluster,O
.,O
The,O
selected,O
variables,O
were,O
used,O
as,O
linear,O
terms,O
in,O
the,O
quasi,O
‐,O
Poisson,PERSON
model,TITLE
.,O
